THERAMEX
A new international survey of 1,008 women with osteoporosis from six countries, launched on World Osteoporosis Day, reveals that while more than two-thirds (67%) of women over the age of 55 mostly understand what osteoporosis is and the potential negative impact of future fractures, 19% felt poorly informed at the time of the diagnosis.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211019005894/en/
The survey initiated by Theramex in cooperation with the International Osteoporosis Foundation (IOF), was conducted in Germany, France, Italy, Spain, Australia, and Brazil. It included 316 postmenopausal women over the age of 55 years and 315 premenopausal women (40-55 years) with osteoporosis (altogether 62% of the surveyed women). Of these women, osteoporosis was only diagnosed after a fracture in almost 60% of the cases. This survey highlights a gap in osteoporosis awareness, as one-fourth of the patients aged 55 years and over were not aware and did not understand the link between osteoporosis and bone fractures.1 A third (35%) of respondents said they would have been motivated to watch out for their bone health if they had known that one in three women aged over 50 will suffer a fragility fracture, but fragility fractures are preventable with the right treatment.1,2 In addition, close to 25% of postmenopausal women felt not listened to by their doctors when discussing their treatment.1
Osteoporosis is a chronic condition causing loss of bone mass and strength, resulting in fragile bones.3 It is a growing problem,3 affecting around 500 million people globally.4 Osteoporosis affects more women than men, with the risk increasing with age.5 Women are at higher risk of osteoporosis after the menopause, when the ovaries stop producing oestrogen, a hormone which has a protective effect on bones.5
Dr. Philippe Halbout, International Osteoporosis Foundation CEO said, “The impact of osteoporosis should not be underestimated. Fractures can be life-altering, causing pain, disability and loss of independence which is why it’s so important to ensure that patients are receiving the information, care and treatment they need to manage their condition and prevent or delay fractures. This survey highlights the need for improved doctor-patient communications and demonstrates the importance of education to empower women to ask for more from their care.”
Theramex CEO, Robert Stewart, commented, “Women with osteoporosis deserve support and appropriate treatment to help them continue to enjoy their lifestyles and precious moments with loved ones. We are committed to working with the osteoporosis community to provide accessible information and education about the condition, as the more women know and understand, the more they will be empowered to ask for more from their osteoporosis care, helping to reduce or eliminate the risk of fractures.”
This World Osteoporosis Day, women are being urged to #askformore from their osteoporosis care and treatment. For further information and osteoporosis resources, visit www.worldosteoporosisday.org
ENDS
NOTES TO EDITOR:
About the survey1
The online survey was conducted among 1,008 women with osteoporosis across six countries: Germany (73), France (74), Spain (122), Italy (298), Australia (54) and Brazil (387). The respondents were all female with 377 under 40, 315 aged 40-54, 201 aged 55-64, 90 aged 65-75 and 25 over 75. It should be noted that the risk of osteoporosis increases with age, despite the number of women in the younger age category in this survey. The survey was conducted between 5 – 12 July 2021 by Opinion Matters on behalf of Theramex.
About Osteoporosis
Osteoporosis remains largely underdiagnosed and undertreated, resulting in a large number of fractures.
- It is a significant health issue – affecting ~500 million people worldwide4
- Osteoporosis affects more women than men and risk increase with age5
- After the menopause women start to lose bone at a faster rate, raising the risk for women who have had an early menopause or hysterectomy5
- One in three women aged over 50 will suffer a fragility fracture2
- Hip, spine, and wrist fractures are the most common fractures in osteoporosis and have a debilitating impact on daily activities and quality of life2
- After a spine fracture, mortality is increased immediately after the fracture event6
- Spine fractures can lead to back pain, loss of height, deformity, immobility, impaired quality of life (QoL), and difficulties in activities of daily living7,8,9
About the International Osteoporosis Foundation (IOF)
The International Osteoporosis Foundation is the world’s largest non-governmental organization dedicated to the prevention, diagnosis, and treatment of osteoporosis and related musculoskeletal diseases.
IOF Vision
Our vision is a world without fragility fractures, in which healthy mobility is a reality for all.
IOF Mission
To promote bone and musculoskeletal health as a worldwide priority.
About Theramex
Theramex is a leading, global speciality pharmaceutical company dedicated to women and their health. With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, we support women at every stage of their lives. Our commitment is to listen and understand our patients, serve their needs, and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them, by providing innovative and effective solutions that care for and support women as they advance through each stage of their lives.
References:
- Opinion Matters. (2021) #Askformore Osteoporosis International Survey.
- Cooper, C. (2019) IOF Compendium of Osteoporosis . IOF. 2nd edition.
- Noh, J.Y., Yang, Y. & Jung, H. (2020) Int J Mol Sci. 21 (20), 7623
- IOF. (n.d.) IOF website Facts and Statistics https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures [Accessed 18th October 2021]
- IOF. (n.d.) About Osteoporosis: Risk Factors. Available from: https://www.osteoporosis.foundation/patients/about-osteoporosis/risk-factors [Accessed 18th October 2021]
- Johnell, O. et al. (2004) Osteoporos Int 15 (1), 38-42.
- Nevitt, M.C. et al. (1998) Ann Intern Med 128 (10), 793-800.
- Lips, P. et al (1999) Osteoporos Int 10, 150-160.
- Tosteson, A.N. et al (2001) Osteoporos Int 12:1042-1049.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005894/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SciencePower Collaborates to Advance Research on Postbiotics in Breast Cancer Biology9.12.2025 13:00:00 CET | Press release
SciencePower, a next-generation postbiotic platform company, today announced that it has entered into a license agreement with Mayo Clinic. The agreement enables collaborative research led by Mayo Clinic investigators to explore the potential of SciencePower’s proprietary postbiotic compositions in breast cancer biology. The collaboration will focus on understanding how specific microbiome-derived compositions influence immune and cellular pathways relevant to breast cancer. Early preclinical findings are currently planned to be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2025. “This milestone marks an important step in validating our technology through rigorous scientific collaboration,” said Robin Albin, SciencePower Co-Founder, Marketing & Communications. “We are honored to work with Mayo Clinic researchers to deepen the understanding of postbiotics and their potential role in advancing human health.” Mayo Clinic has a financial interest in SciencePower
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET9.12.2025 12:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will host a webinar to discuss the company’s commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD) from 10:00-11:30 am ET on January 7, 2026. The discussion will include KOL and industry leaders’ perspectives on the current treatment landscape and the significant unmet need in treating both TRD and PTSD. The company’s collaboration partners will discuss patient care pathways, provider economics for multi-hour treatments, and the development of treatment models in TRD. Compass Pathways’ management team will review commercial readiness activities and the emerging profile of COMP360 in TRD, as well as highlight the unmet need in post-traumatic stress disorder (PTSD) and provide details of the planned late-stage program for COMP360 in
Brands Poised for Growth: NIQ Identifies the Strategies Behind 2025’s Top Performing Innovations9.12.2025 12:00:00 CET | Press release
New analysis of 70,000+ manufacturers reveal the practices that double a brand’s chances of sustained sales growth. NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today released its 4th Annual Innovation Vitality Report, revealing the strategies that are helping brands achieve multi-year growth from their innovation pipelines. Drawing on data from over 70,000 manufacturers across 130 categories, the report highlights the practices that double a company’s likelihood of expanding overall sales through top performing innovation. As retailers accelerate shelf refresh cycles and private label competition intensifies, brands are under increasing pressure to design innovations with staying power. NIQ’s findings show that top performing innovators consistently follow a repeatable formula, rooted in strong consumer-led ideas, early performance signals, and cross functional alignment, to build products that deliver long-term, incremental growth across global markets. Key Findin
Klarna Now Available on Apple Pay to Customers in France and Italy9.12.2025 11:49:00 CET | Press release
Klarna now live on Apple Pay in 8 countries — offering millions of consumers the ability to pay with installments when checking out online, in-app and in-person with Apple Pay Klarna, the global digital bank and flexible payments provider, has made its flexible payment products available when checking out on Apple Pay in France and Italy. Millions of eligible shoppers can now choose Klarna at checkout online and in-app using their iPhone and iPad, or in-store using their iPhone, and this innovative capability delivers even more convenience, control, and transparency to even more customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209410835/en/ The continued expansion follows strong consumer adoption and momentum in Denmark, Spain, Sweden, the U.S., UK and Canada, where Klarna’s flexible payment options have become a popular way to pay with Apple Pay. With today’s launch, consumers across eight major markets can now
DNP Achieves 10nm Line Pattern Resolution on Nanoimprint Template for Cutting-Edge Semiconductors9.12.2025 11:12:00 CET | Press release
- Supports 1.4nm Generation Semiconductors, Reduces Manufacturing Costs and Energy Consumption - Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced the development of a nanoimprint lithography (NIL) template featuring a circuit line width of 10 nanometers (nm: 10-9 meter). The new template enables patterning for logic semiconductors equivalent to the 1.4nm generation and meets the miniaturization needs of cutting-edge logic semiconductors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208175160/en/ Template for nanoimprint Background and Aims In line with the shift to more sophisticated devices seen in recent years, demands have emerged for even greater miniaturization in cutting-edge semiconductors, leading to advances in Extreme Ultra-Violet (EUV) lithography-based production. EUV lithography, however, requires substantial capital investment, energy consumption, and operating costs in building production l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
